Home LiteratureArticle Details
PMID: 18424754 Published · ppublish English Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Generation of anaphylatoxins by human beta-tryptase from C3, C4, and C5.

Journal of immunology (Baltimore, Md. : 1950) ·Vol. 180 ·No. 9 ·2008-05-01 ·Pages 6307-16

Fukuoka Y, Xia HZ, Sanchez-Muñoz LB, Dellinger AL, Escribano L, Schwartz LB

Abstract

Both mast cells and complement participate in innate and acquired immunity. The current study examines whether beta-tryptase, the major protease of human mast cells, can directly generate bioactive complement anaphylatoxins. Important variables included pH, monomeric vs tetrameric forms of beta-tryptase, and the beta-tryptase-activating polyanion. The B12 mAb was used to stabilize beta-tryptase in its monomeric form. C3a and C4a were best generated from C3 and C4, respectively, by monomeric beta-tryptase in the presence of low molecular weight dextran sulfate or heparin at acidic pH. High molecular weight polyanions increased degradation of these anaphylatoxins. C5a was optimally generated from C5 at acidic pH by beta-tryptase monomers in the presence of high molecular weight dextran sulfate and heparin polyanions, but also was produced by beta-tryptase tetramers under these conditions. Mass spectrometry verified that the molecular mass of each anaphylatoxin was correct. Both beta-tryptase-generated C5a and C3a (but not C4a) were potent activators of human skin mast cells. These complement anaphylatoxins also could be generated by beta-tryptase in releasates of activated skin mast cells. Of further biologic interest, beta-tryptase also generated C3a from C3 in human plasma at acidic pH. These results suggest beta-tryptase might generate complement anaphylatoxins in vivo at sites of inflammation, such as the airway of active asthma patients where the pH is acidic and where elevated levels of beta-tryptase and complement anaphylatoxins are detected.

MeSH Terms
Anaphylatoxins/biosynthesis,chemistry Antibodies, Monoclonal/chemistry Asthma/enzymology Complement C3/chemistry,metabolism Complement C4/chemistry,metabolism Complement C5/chemistry,metabolism Dextran Sulfate/chemistry,metabolism Heparin/chemistry,metabolism Humans Hydrogen-Ion Concentration Immunity, Innate Mast Cells/chemistry,metabolism Protein Structure, Quaternary Skin/chemistry,metabolism Tryptases/chemistry,metabolism
Chemicals
Anaphylatoxins Antibodies, Monoclonal Complement C3 Complement C4 Complement C5 Heparin Dextran Sulfate Tryptases
Authors & Affiliations
6 authors, click to expand affiliations / ORCID
Fukuoka Yoshihiro
Division of Rheumatology, Allergy and Immunology, Department of Internal Medicine, Virginia Commonwealth University, Richmond, VA 23298, USA.
Xia Han-Zhang
Sanchez-Muñoz Laura B
Dellinger Anthony L
Escribano Luis
Schwartz Lawrence B
References (73)
73 references, click to expand
  1. Expression of the anaphylatoxin receptors C3aR and C5aR is increased in fatal asthma.
    J Allergy Clin Immunol. 2005 Jun;115(6):1148-54 PMID: 15940127
  2. A novel heparin-dependent processing pathway for human tryptase. Autocatalysis followed by activation with dipeptidyl peptidase I.
    J Clin Invest. 1996 Feb 15;97(4):988-95 PMID: 8613553
  3. Inhibition of complement activation decreases airway inflammation and hyperresponsiveness.
    Am J Respir Crit Care Med. 2003 Dec 1;168(11):1333-41 PMID: 14500265
  4. C5A anaphylatoxin and its seven transmembrane-segment receptor.
    Annu Rev Immunol. 1994;12:775-808 PMID: 8011297
  5. Complement factors and their receptors.
    Immunopharmacology. 1997 Dec;38(1-2):3-15 PMID: 9476110
  6. Airway remodeling: a comparison between fatal and nonfatal asthma.
    J Asthma. 2004 Sep;41(6):631-8 PMID: 15584312
  7. Evidence for elevated levels of histamine, prostaglandin D2, and other bronchoconstricting prostaglandins in the airways of subjects with mild asthma.
    Am Rev Respir Dis. 1990 Jul;142(1):126-32 PMID: 2368958
  8. FcepsilonR1 and toll-like receptors mediate synergistic signals to markedly augment production of inflammatory cytokines in murine mast cells.
    Blood. 2006 Jan 15;107(2):610-8 PMID: 16174756
  9. Fc gamma RIIa, not Fc gamma RIIb, is constitutively and functionally expressed on skin-derived human mast cells.
    J Immunol. 2006 Jul 1;177(1):694-701 PMID: 16785568
  10. Identification of chondroitin sulfate E in human lung mast cells.
    J Immunol. 1988 Apr 15;140(8):2708-13 PMID: 3356902
  11. Mast cell accumulation at sites of murine tumor implantation: implications for angiogenesis and tumor metastasis.
    Invasion Metastasis. 1994-1995;14(1-6):395-408 PMID: 7544776
  12. Immunologic and physicochemical evidence for conformational changes occurring on conversion of human mast cell tryptase from active tetramer to inactive monomer. Production of monoclonal antibodies recognizing active tryptase.
    J Immunol. 1990 Mar 15;144(6):2304-11 PMID: 2179409
  13. Human tryptase fibrinogenolysis is optimal at acidic pH and generates anticoagulant fragments in the presence of the anti-tryptase monoclonal antibody B12.
    J Immunol. 1997 Oct 1;159(7):3540-8 PMID: 9317153
  14. Angiogenesis and mast cell density with tryptase activity increase simultaneously with pathological progression in B-cell non-Hodgkin's lymphomas.
    Int J Cancer. 2000 Jan 15;85(2):171-5 PMID: 10629073
  15. Activation of mast cells by double-stranded RNA: evidence for activation through Toll-like receptor 3.
    J Allergy Clin Immunol. 2004 Jul;114(1):174-82 PMID: 15241362
  16. Tryptase genetics and anaphylaxis.
    J Allergy Clin Immunol. 2006 Jun;117(6):1411-4 PMID: 16751005
  17. C5 chemotactic fragments produced by an enzyme in lysosomal granules of neutrophils.
    J Immunol. 1970 Mar;104(3):535-43 PMID: 4985169
  18. Human beta-tryptase is a ring-like tetramer with active sites facing a central pore.
    Nature. 1998 Mar 19;392(6673):306-11 PMID: 9521329
  19. Chemotactic activity generated from the fifth component of complement by plasma kallikrein of the rabbit.
    J Exp Med. 1981 Jun 1;153(6):1391-404 PMID: 6910482
  20. Inflammatory mast cells up-regulate angiogenesis during squamous epithelial carcinogenesis.
    Genes Dev. 1999 Jun 1;13(11):1382-97 PMID: 10364156
  21. Mast cell involvement in normal human skin wound healing: expression of monocyte chemoattractant protein-1 is correlated with recruitment of mast cells which synthesize interleukin-4 in vivo.
    J Pathol. 2000 Jan;190(1):100-6 PMID: 10640999
  22. Human mast cells stimulate vascular tube formation. Tryptase is a novel, potent angiogenic factor.
    J Clin Invest. 1997 Jun 1;99(11):2691-700 PMID: 9169499
  23. Toll-like receptor 2 (TLR2) and TLR4 differentially activate human mast cells.
    Eur J Immunol. 2003 Apr;33(4):899-906 PMID: 12672055
  24. The catalytically active serine protease domain of human complement factor I.
    Biochemistry. 2005 Apr 26;44(16):6239-49 PMID: 15835912
  25. Mast cells and dendritic cells in basal cell carcinoma stroma.
    Dermatol Surg. 2000 Mar;26(3):200-3; discussion 203-4 PMID: 10759793
  26. Tryptase-positive mast cells correlate positively with bone marrow angiogenesis in B-cell chronic lymphocytic leukemia.
    Leukemia. 2003 Jul;17(7):1428-30 PMID: 12835741
  27. Human complement factor I does not require cofactors for cleavage of synthetic substrates.
    J Immunol. 2004 Jul 1;173(1):367-75 PMID: 15210795
  28. Mast cell tryptases and chymases in inflammation and host defense.
    Immunol Rev. 2007 Jun;217:141-54 PMID: 17498057
  29. Complement peptides C3a- and C5a-induced mediator release from dissociated human skin mast cells.
    J Invest Dermatol. 1994 May;102(5):803-6 PMID: 7513741
  30. Identification of neutrophil chemotactic factors in bronchoalveolar lavage fluid of asthmatic patients.
    Clin Exp Allergy. 1997 Apr;27(4):396-405 PMID: 9146932
  31. Formation of active monomers from tetrameric human beta-tryptase.
    Biochem J. 2003 Feb 1;369(Pt 3):603-10 PMID: 12387726
  32. Mast cell density is associated with angiogenesis and poor prognosis in pulmonary adenocarcinoma.
    Cancer. 2000 Jun 15;88(12):2686-92 PMID: 10870050
  33. Complement factors c3a, c4a, and c5a in chronic obstructive pulmonary disease and asthma.
    Am J Respir Cell Mol Biol. 2004 Aug;31(2):216-9 PMID: 15039137
  34. Identification of specific gene expression profiles in human mast cells mediated by Toll-like receptor 4 and FcepsilonRI.
    Blood. 2003 Oct 1;102(7):2547-54 PMID: 12855579
  35. Complement factors C3a and C5a are increased in bronchoalveolar lavage fluid after segmental allergen provocation in subjects with asthma.
    Am J Respir Crit Care Med. 2001 Nov 15;164(10 Pt 1):1841-3 PMID: 11734433
  36. Nucleophilic modification of human complement protein C3: correlation of conformational changes with acquisition of C3b-like functional properties.
    Biochemistry. 1981 Jul 21;20(15):4458-67 PMID: 7284336
  37. Expression of the complement anaphylatoxin C3a and C5a receptors on bronchial epithelial and smooth muscle cells in models of sepsis and asthma.
    J Immunol. 2001 Feb 1;166(3):2025-32 PMID: 11160252
  38. Acid hydrolases and tryptase from secretory granules of dispersed human lung mast cells.
    J Immunol. 1981 Apr;126(4):1290-4 PMID: 7009736
  39. Mast cells and their mediators in cutaneous wound healing--active participants or innocent bystanders?
    Exp Dermatol. 1999 Feb;8(1):1-16 PMID: 10206716
  40. Human beta-tryptase: detection and characterization of the active monomer and prevention of tetramer reconstitution by protease inhibitors.
    Biochemistry. 2004 Aug 24;43(33):10757-64 PMID: 15311937
  41. Release of mast-cell-derived mediators after endobronchial adenosine challenge in asthma.
    Am J Respir Crit Care Med. 1995 Mar;151(3 Pt 1):624-9 PMID: 7881647
  42. Mast-cell infiltration of airway smooth muscle in asthma.
    N Engl J Med. 2002 May 30;346(22):1699-705 PMID: 12037149
  43. Human skin-derived mast cells can proliferate while retaining their characteristic functional and protease phenotypes.
    Blood. 2001 Apr 1;97(7):2045-52 PMID: 11264170
  44. ELISA of complement C3a in bronchoalveolar lavage fluid.
    J Immunol Methods. 1992 Mar 4;147(2):241-50 PMID: 1548406
  45. Ultrastructural localization of heparin to human mast cells of the MCTC and MCT types by labeling with antithrombin III-gold.
    Lab Invest. 1993 Nov;69(5):552-61 PMID: 8246447
  46. Cellular receptors to the anaphylatoxins C3a and C5a.
    Biochem Soc Symp. 1986;51:69-81 PMID: 3545212
  47. Identification of sulfated mucopolysaccharides including heparin in the lesional skin of a patient with mastocytosis.
    J Invest Dermatol. 1980 Apr;74(4):210-5 PMID: 6445388
  48. Alterations in mast cells showing tryptase and chymase activity in epithelializating and chronic wounds.
    Exp Dermatol. 2000 Aug;9(4):258-65 PMID: 10949547
  49. A role for the C3a anaphylatoxin receptor in the effector phase of asthma.
    Nature. 2000 Aug 31;406(6799):998-1001 PMID: 10984054
  50. Mast cells enhance migration and proliferation of fibroblasts into an in vitro wound.
    Exp Cell Res. 1990 May;188(1):42-9 PMID: 2328776
  51. The role of the mast cell in the pathophysiology of asthma.
    J Allergy Clin Immunol. 2006 Jun;117(6):1277-84 PMID: 16750987
  52. Immunologic release of beta-hexosaminidase and beta-glucuronidase from purified rat serosal mast cells.
    J Immunol. 1979 Oct;123(4):1445-50 PMID: 479592
  53. Generation of C5a by phagocytic cells.
    Am J Pathol. 2002 Nov;161(5):1849-59 PMID: 12414531
  54. Development of a new, more sensitive immunoassay for human tryptase: use in systemic anaphylaxis.
    J Clin Immunol. 1994 May;14(3):190-204 PMID: 7929694
  55. Surface CD88 functionally distinguishes the MCTC from the MCT type of human lung mast cell.
    J Allergy Clin Immunol. 2005 Jun;115(6):1162-8 PMID: 15940129
  56. Generation of anaphylatoxins through proteolytic processing of C3 and C5 by house dust mite protease.
    J Allergy Clin Immunol. 1997 Aug;100(2):253-60 PMID: 9275149
  57. Endogenous airway acidification. Implications for asthma pathophysiology.
    Am J Respir Crit Care Med. 2000 Mar;161(3 Pt 1):694-9 PMID: 10712309
  58. Cutting edge: distinct Toll-like receptor 2 activators selectively induce different classes of mediator production from human mast cells.
    J Immunol. 2003 Feb 15;170(4):1625-9 PMID: 12574323
  59. MRI of the tumor microenvironment.
    J Magn Reson Imaging. 2002 Oct;16(4):430-50 PMID: 12353258
  60. Human cutaneous mast cells express basic fibroblast growth factor.
    Lab Invest. 1995 Feb;72(2):215-22 PMID: 7531794
  61. Identification of complement factor 5 as a susceptibility locus for experimental allergic asthma.
    Nat Immunol. 2000 Sep;1(3):221-6 PMID: 10973279
  62. Activation of pulmonary mast cells by bronchoalveolar allergen challenge. In vivo release of histamine and tryptase in atopic subjects with and without asthma.
    Am Rev Respir Dis. 1988 May;137(5):1002-8 PMID: 2461667
  63. Isolation and characterization of heparin from human lung.
    J Clin Invest. 1979 Dec;64(6):1537-43 PMID: 500822
  64. Expression of C5a-like biological activities by the fifth component of human complement (C5) upon limited digestion with noncomplement enzymes without release of polypeptide fragments.
    J Exp Med. 1983 Jun 1;157(6):2029-48 PMID: 6222137
  65. The accelerating effect of histamine on the cutaneous wound-healing process through the action of basic fibroblast growth factor.
    J Invest Dermatol. 2006 Jun;126(6):1403-9 PMID: 16543894
  66. The B12 anti-tryptase monoclonal antibody disrupts the tetrameric structure of heparin-stabilized beta-tryptase to form monomers that are inactive at neutral pH and active at acidic pH.
    J Immunol. 2006 Mar 1;176(5):3165-72 PMID: 16493076
  67. Generation of C3a anaphylatoxin from human C3 by human mast cell tryptase.
    J Immunol. 1983 Apr;130(4):1891-5 PMID: 6339618
  68. Altered expression of mast cell chymase and tryptase and of c-Kit in human cutaneous scar tissue.
    J Invest Dermatol. 2000 Jan;114(1):51-5 PMID: 10620115
  69. Increased mast cells and neutrophils in submucosal mucous glands and mucus plugging in patients with asthma.
    Thorax. 2002 Aug;57(8):677-82 PMID: 12149526
  70. Interactions of human mast cell tryptase with biological protease inhibitors.
    Arch Biochem Biophys. 1990 Jan;276(1):26-31 PMID: 1688695
  71. Mast cells correlate with angiogenesis and poor outcome in stage I lung adenocarcinoma.
    Eur Respir J. 2000 Jun;15(6):1087-93 PMID: 10885428
  72. Tryptase precursors are preferentially and spontaneously released, whereas mature tryptase is retained by HMC-1 cells, Mono-Mac-6 cells, and human skin-derived mast cells.
    J Immunol. 2003 Jun 1;170(11):5667-73 PMID: 12759448
  73. Generation of C5a in the absence of C3: a new complement activation pathway.
    Nat Med. 2006 Jun;12(6):682-7 PMID: 16715088
Article Info
Journal
Journal of immunology (Baltimore, Md. : 1950)
Abbr.
J Immunol
ISSN
0022-1767
Published
2008-05-01
Pages
6307-16
Language
English
Region
United States
NLM ID
2985117R
PMCID
PMC2645414
Subset
IM
Grants
NIAID NIH HHS · R01 AI027517 · United States
NIAID NIH HHS · R01 AI027517-19 · United States
NIAID NIH HHS · U19 AI077435 · United States
NIAID NIH HHS · R01 AI020487 · United States
NIAID NIH HHS · U19 AI077435-010001 · United States
NIAID NIH HHS · R01 AI 27517 · United States
NIAID NIH HHS · R01 AI020487-22 · United States
NIAID NIH HHS · R01 AI027517-18 · United States
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]